Corsair
Corsair is TransMed7’s baseline application of Zero5 technology to vascular intervention.
This next generation platform offers a host of advantages for future vascular intervention platforms currently under development by TransMed7
The Technology
Based on TransMed7’s forward-cutting, forward-coring Zero5 technology, Corsair is a next-generation, complete vascular atherectomy solution for chronic total and subtotal occlusions and total disease removal.
- Wide open central lumen enables unlimited tissue removal without the need to remove the device while tissue samples are collected and transported
- Treat occlusions in coronary vessels (blood vessels in the heart itself) that lead to heart attacks and heart failure, as well as peripheral vessels (in the limbs) which lead to decreased blood supply that may cause pain, limb damage and limb loss
- Treat occlusions in vessels too small for current technologies
- Treat in-stent restenosis, where occlusions recur
- Designed to deliver the most cost-effective and durable vascular intervention solution, with or without additional pharmacologic and vascular wall stabilizing adjunctive treatments
The Future: TransVascular Dynamics, Inc.
Corsair is the baseline technology for TransMed7’s newest Project Company – TransVascular Dynamics, Inc. (TVDI). TransVascular Dynamics will be the recipient platform for all of TransMed7’s patented cardiovascular intervention devices, which will include our Nautilus, Hurricane, Warhawk, Mustang, Zepp II, LZ 127 and other technologies under development – covering new segmented drug eluting balloons, advanced atherectomy devices incorporating In Vivo Microscopy imaging and other modalities, vascular filtration systems and other key technologies that will redefine vascular intervention and advanced healing mechanisms for better patient treatment options.
Want to Know More?
please reach out to us using the form below.